NCT00110045View on ClinicalTrials.gov

Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant

PHASE2CompletedINTERVENTIONAL
Enrollment

171

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

March 31, 2008

Conditions
Cancer
Interventions
DRUG

caspofungin acetate

Trial Locations (13)

12100

Ospedale Santa Croce, Cuneo

16132

Istituto Nazionale per la Ricerca sul Cancro, Genoa

Ospedale San Martino, Genoa

67098

Hopital Universitaire Hautepierre, Strasbourg

69437

Hopital Edouard Herriot - Lyon, Lyon

75475

Hopital Saint-Louis, Paris

94010

Centre Hospitalier Universitaire Henri Mondor, Créteil

B-4000

CHU Liege - Domaine Universitaire du Sart Tilman, Liège

D-97070

Medizinische Poliklinik, Universitaet Wuerzburg, Würzburg

00168

Policlinico A. Gemelli - Universita Cattolica del Sacro Cuore, Rome

833 10

National Cancer Institute - Bratislava, Bratislava

CH-1011

Centre Hospitalier Universitaire Vaudois, Lausanne

06100

Hacettepe University - Faculty of Medicine, Ankara

All Listed Sponsors
lead

European Organisation for Research and Treatment of Cancer - EORTC

NETWORK

NCT00110045 - Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant | Biotech Hunter | Biotech Hunter